Dark

Check out our Level2View

BCDAW
BioCardia, Inc. Warrant
stock NASDAQ

Inactive

Aug 2, 2024

0.0061USD-1.613%(-0.0001)15,512

Pre-market

0.00USD-100.000%(-0.01)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 17, 2020

08:30AM EST BioCardia Announces Positive DSMB Review and Recommendation to GlobeNewswire Inc

Nov 10, 2020

07:00AM EST BioCardia, Inc.[NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and business highlights for the third quarter of 2020 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 with the Securities and Exchange Commission on November 10, 2020. GlobeNewswire Inc

Oct 26, 2020

07:30AM EDT Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months GlobeNewswire Inc

Sep 29, 2020

08:00AM EDT BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy GlobeNewswire Inc

Aug 26, 2020

07:00AM EDT BioCardia to Present at the LD Micro 500 Virtual Conference on GlobeNewswire Inc

Aug 13, 2020

07:00AM EDT BioCardia, Inc.[NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter of 2020 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2020 with the Securities and Exchange Commission on August 13, 2020. GlobeNewswire Inc

Aug 7, 2020

08:00AM EDT BioCardia, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it will be conducting a mid-year corporate update conference call on Thursday, August 13, 2020 at 8:30AM ET. Following managements formal remarks, there will be a question and answer session. GlobeNewswire Inc

Share